Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP.
BACKGROUND
Little is known on racial differences in patients with diffuse large B-cell lymphoma (DLBCL). The aim of this retrospective study is to compare characteristics, prognostic factors and outcomes of Asian and Western patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP).


METHODS
Patient-level data was collected from 8 centers. All patients were diagnosed with DLBCL and treated with R-CHOP. Patients were divided into Asian and Western, according to the country of report. Comparisons and univariate/multivariate survival analyses were performed.


RESULTS
712 patients, 455 Asian and 257 Western patients were included. Westerners were more likely to present with elevated LDH (64% vs. 48%, p<0.01) and advanced stage (58% vs. 49%, p<0.01). After a median follow-up of 36 months, there was no difference in progression-free (PFS; p=0.33) or overall survival (OS; p=0.69). There were no PFS or OS differences between races when evaluating separately each age-adjusted International Prognostic Index category. In the multivariate analyses, performance status and stage were associated with PFS and OS in both races.


CONCLUSIONS
There are no differences in prognostic factors, PFS and OS between Asian and Western patients with DLBCL treated with R-CHOP.
Division of Hematology and Oncology, Rhode Island Hospital/The Miriam Hospital, Providence, RI 02906, USA. jcastillo@lifespan.org
Jorge J
JJ
Castillo
Natalie
N
Sinclair
Brady E
BE
Beltrán
Moo-Kon
MK
Song
Ivana
I
Ilic
Sirpa
S
Leppa
Heidi
H
Nurmi
Ritsuko
R
Seki
Silvia
S
Uccella
Jun-Min
JM
Li
Diana O
DO
Treaba
Dariusz
D
Stachurski
James N
JN
Butera
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001208:Asia; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005060:Europe; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone